Sagimet Biosciences Inc. (SGMT) surged 14.60 percent to $4.16 on Wednesday, gaining $0.41 after announcing positive results from a Phase 3 clinical trial of denifanstat for moderate to severe acne vulgaris. The trial, conducted by its Chinese license partner Ascletis Bioscience, met all primary and secondary endpoints. SGMT opened at $4.02 and traded between $3.83 and $4.64 during the session on the Nasdaq. The stock's 52-week range is $1.73 to $7.38, with volume spiking to 19.7 million shares, well above its average of 480,482.
Denifanstat, also known as ASC40 in China, is a once-daily oral FASN inhibitor. While Ascletis develops the drug for acne in China, Sagimet is advancing it globally for metabolic dysfunction-associated steatohepatitis. The company also recently began a Phase 1 clinical trial in the U.S. for a second FASN inhibitor, TVB-3567, targeting acne.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.